Skip to main content

Table 2 Persistence of pregabalin during follow-up

From: Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study

  

Duration of persistence (days)

No. of patients with persistent pregabalin use

 

No. of patients

Mean (SD)

Median (IQR)

> = 90 days

~ < 180 days

> = 180 days

~ < 1 year

> = 1 year

~ < 2 years

> = 2 years

All cohort

114,437

149.5 (299.8)

28 (14–118)

33,570 (29.3)

22,201 (19.4)

13,885 (12.1)

33,570 (29.3)

Specialties

Neurology

53,910

179.3 (330.4)

41 (14–161)

18,423 (34.2)

12,623 (23.4)

8165 (15.1)

18,423 (34.2)

Anesthesiology

5541

189.8 (358)

42 (14–166)

1928 (34.8)

1302 (23.5)

829 (15)

1928 (34.8)

Physiatry

3151

143.4 (301.1)

28 (14–99)

845 (26.8)

566 (18)

364 (11.6)

845 (26.8)

Psychiatry

430

222.8 (383.9)

56 (21–209)

162 (37.7)

117 (27.2)

80 (18.6)

162 (37.7)

Rheumatology

9201

206.6 (366.3)

47 (21–191)

3444 (37.4)

2388 (26)

1558 (16.9)

3444 (37.4)

Others

42,204

93.3 (211.3)

22 (7–69)

8768 (20.8)

5205 (12.3)

2889 (6.8)

8768 (20.8)

Indications

Herpes zoster

34,919

89.4 (224.1)

21 (7–56)

6405 (18.3)

3700 (10.6)

2134 (6.1)

6405 (18.3)

Diabetic peripheral neuropathic pain

13,369

221.9 (330.1)

71 (28–294)

6044 (45.2)

4381 (32.8)

2894 (21.6)

6044 (45.2)

Fibromyalgia

21,051

150.8 (302.8)

28 (14–117)

6179 (29.4)

4026 (19.1)

2470 (11.7)

6179 (29.4)

Epilepsy

3301

515.5 (603.5)

220 (35–814)

2085 (63.2)

1748 (53)

1400 (42.4)

2085 (63.2)

Other musculoskeletal diseases

24,227

138.3 (269.8)

30 (14–113)

7141 (29.5)

4499 (18.6)

2638 (10.9)

7141 (29.5)

Others

17,570

158.6 (295.9)

35 (14–141)

5716 (32.5)

3847 (21.9)

2349 (13.4)

5716 (32.5)